Related Experiment Video
Updated: Mar 27, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Intravenous thrombolytic therapy for patients with ventricular assist device thrombosis: An attempt to avoid
Beth T Webber1, Anthony L Panos, Yiliam F Rodriguez-Blanco
1Department of Anesthesia, Division of Cardiovascular Anesthesia, University of Miami, Florida, USA.
Insights
Left ventricular assist device (LVAD) pump thrombosis is an increasing complication. This case study shows successful thrombolysis using tissue plasminogen activator in the ICU.
Area of Science:
- Cardiology
- Medical Devices
- Critical Care Medicine
Background:
- Continuous flow left ventricular assist devices (LVADs) are increasingly used for advanced heart failure management.
- A growing number of patients require prolonged LVAD support, leading to a rise in device-related complications.
- LVAD pump thrombosis is a significant and feared complication with challenging management strategies.
Observation:
- LVAD pump thrombosis incidence may be higher than previously estimated, based on data from major LVAD centers.
- Patients with LVADs often have complex comorbidities, complicating treatment decisions.
- Standard protocols, such as increased anticoagulation, may not effectively resolve thrombus.
Findings:
- Successful thrombolysis was achieved through intravenous administration of tissue plasminogen activator.
- Treatment was successfully administered in the Intensive Care Unit (ICU) setting.
- This approach offers an alternative to reoperation, which carries significant risks and poor prognosis.
Implications:
- Intravenous thrombolysis with tissue plasminogen activator presents a viable treatment option for LVAD pump thrombosis.
- This method may improve outcomes for patients experiencing this severe LVAD complication.
- Further research into optimal thrombolytic strategies for LVAD patients is warranted.
Abstract:
A growing number of patients are undergoing prolonged management of advanced heart failure with the use of continuous flow left ventricular assist devices (LVADs). Subsequently, an increasing number of patients are presenting with complications associated with these devices. Based on an analysis of three major LVAD institutions, the number of patients developing LVAD pump thrombosis may be much higher than originally projected. [1],[2] The management of this highly feared complication continues to be challenging, as the population of LVAD patients is very heterogeneous and heavily burdened with comorbidities. The standard protocol of increasing anticoagulation may fail to achieve successful resolution of thrombus. Difficulty and poor prognosis may make reoperation less than desirable. Here, we present a case of successful thrombolysis following intravenous administration of tissue plasminogen activator in the Intensive Care Unit setting.
More Related Videos
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism III: Nursing Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care